141 related articles for article (PubMed ID: 26181639)
1. Pharmacogenetics and individual responses to treatment of hyperglycemia in type 2 diabetes.
Engelbrechtsen L; Andersson E; Roepstorff S; Hansen T; Vestergaard H
Pharmacogenet Genomics; 2015 Oct; 25(10):475-84. PubMed ID: 26181639
[TBL] [Abstract][Full Text] [Related]
2. [Pharmacogenetics of oral antidiabetic treatment].
Tkáč I
Vnitr Lek; 2016 Mar; 62(3):186-8. PubMed ID: 27180666
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective.
Manolopoulos VG; Ragia G; Tavridou A
Pharmacogenomics; 2011 Aug; 12(8):1161-91. PubMed ID: 21843065
[TBL] [Abstract][Full Text] [Related]
4. Genetic susceptibility to type 2 diabetes and implications for antidiabetic therapy.
Moore AF; Florez JC
Annu Rev Med; 2008; 59():95-111. PubMed ID: 17937592
[TBL] [Abstract][Full Text] [Related]
5. [Progress in diabetes genetics].
Njølstad PR; Hertel JK; Søvik O; Raeder H; Johansson S; Molven A
Tidsskr Nor Laegeforen; 2010 Jun; 130(11):1145-9. PubMed ID: 20531501
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetics of oral antidiabetic treatment.
Schroner Z; Javorsky M; Kozarova M; Tkac I
Bratisl Lek Listy; 2011; 112(8):441-6. PubMed ID: 21863614
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics of oral antidiabetic therapy.
Ordelheide AM; Hrabě de Angelis M; Häring HU; Staiger H
Pharmacogenomics; 2018 Apr; 19(6):577-587. PubMed ID: 29580198
[TBL] [Abstract][Full Text] [Related]
8. Genetic polymorphisms in diabetes: influence on therapy with oral antidiabetics.
Glamočlija U; Jevrić-Čaušević A
Acta Pharm; 2010 Dec; 60(4):387-406. PubMed ID: 21169132
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics and future strategies in treating hyperglycaemia in diabetes.
Pearson ER
Front Biosci (Landmark Ed); 2009 Jan; 14(11):4348-62. PubMed ID: 19273354
[TBL] [Abstract][Full Text] [Related]
10. KCNJ11 gene E23K variant and therapeutic response to sulfonylureas.
Javorsky M; Klimcakova L; Schroner Z; Zidzik J; Babjakova E; Fabianova M; Kozarova M; Tkacova R; Salagovic J; Tkac I
Eur J Intern Med; 2012 Apr; 23(3):245-9. PubMed ID: 22385882
[TBL] [Abstract][Full Text] [Related]
11. [Treatment of hyperglycemia in adult-onset diabetes mellitus].
Yki-Järvinen H
Duodecim; 1999; 115(10):1155-64. PubMed ID: 11877855
[No Abstract] [Full Text] [Related]
12. [Drug therapy of hyperglycemia and the prognosis of adult-onset diabetes mellitus].
Niskanen L; Uusitupa M; Laakso M
Duodecim; 1999; 115(10):1122-4. PubMed ID: 11877851
[No Abstract] [Full Text] [Related]
13. Managing hyperglycemia in patients with type 2 diabetes mellitus: rationale for the use of dipeptidyl peptidase-4 inhibitors in combination with other oral antidiabetic drugs.
Freeman JS
J Am Osteopath Assoc; 2010 Sep; 110(9):528-37. PubMed ID: 20876838
[TBL] [Abstract][Full Text] [Related]
14. SGLT2: a potential target for the pharmacogenetics of Type 2 diabetes?
Tönjes A; Kovacs P
Pharmacogenomics; 2013 May; 14(7):825-33. PubMed ID: 23651029
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetics of type 2 diabetes mellitus, the route toward tailored medicine.
Mannino GC; Andreozzi F; Sesti G
Diabetes Metab Res Rev; 2019 Mar; 35(3):e3109. PubMed ID: 30515958
[TBL] [Abstract][Full Text] [Related]
16. The E23K variant of KCNJ11 encoding the pancreatic beta-cell adenosine 5'-triphosphate-sensitive potassium channel subunit Kir6.2 is associated with an increased risk of secondary failure to sulfonylurea in patients with type 2 diabetes.
Sesti G; Laratta E; Cardellini M; Andreozzi F; Del Guerra S; Irace C; Gnasso A; Grupillo M; Lauro R; Hribal ML; Perticone F; Marchetti P
J Clin Endocrinol Metab; 2006 Jun; 91(6):2334-9. PubMed ID: 16595597
[TBL] [Abstract][Full Text] [Related]
17. Genetics of drug response in type 2 diabetes.
Tkáč I
Curr Diab Rep; 2015 Jul; 15(7):43. PubMed ID: 25975599
[TBL] [Abstract][Full Text] [Related]
18. Precision medicine: The future in diabetes care?
Scheen AJ
Diabetes Res Clin Pract; 2016 Jul; 117():12-21. PubMed ID: 27329017
[TBL] [Abstract][Full Text] [Related]
19. Understanding the Pathogenesis, Therapeutic Targets/Drug Action and Pharmacogenetics of Type 2 Diabetes: Is there a Future for Personalised Medicine?
Engwa GA; Nweke FN; Karngong GN; Afiukwa CA; Nwagu KE
Endocr Metab Immune Disord Drug Targets; 2020; 20(10):1569-1589. PubMed ID: 32334506
[TBL] [Abstract][Full Text] [Related]
20. Pharmacogenetics and personalized treatment of type 2 diabetes.
Semiz S; Dujic T; Causevic A
Biochem Med (Zagreb); 2013; 23(2):154-71. PubMed ID: 23894862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
